LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the “Company” or “Inotek”), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Inotek senior management, including David P. Southwell, President and Chief Executive Officer, William K. McVicar, Ph.D., Executive Vice President, Chief Scientific Officer, and Claudine Prowse, Ph.D., Vice President, Strategy and Investor Relations Officer, will participate in a fireside chat discussion at the Piper Jaffray 27th Annual Healthcare Conference on December 2, 2015, at 12:00 p.m. Eastern Time at The New York Palace, in New York, NY.
About Inotek Pharmaceuticals Corporation
Inotek
Pharmaceuticals is a clinical stage biopharmaceutical company focused on
the discovery, development and commercialization of therapies for
glaucoma and other eye diseases. The Company's lead product candidate, trabodenoson,
is a first-in-class selective adenosine mimetic currently in Phase 3
development. Trabodenoson was developed in Inotek's laboratories
and designed to restore the eye's natural pressure control mechanism.
The development of trabodenoson monotherapy delivered in a
once-daily eye drop formulation will be followed by a fixed-dose
combination of trabodenoson with latanoprost.
Additionally, the Company is evaluating the potential for selective
adenosine mimetics to address optic neuropathies and other degenerative
retinal diseases.
For more information, please visit www.inotekpharma.com.
